HCW Biologics IncNASDAQ:HCWB
- LAST PRICE1.6600
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.2900/ 2
- Ask / Lots1.6400/ 3
- Open / Previous Close0.0000 / 1.6600
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | HCWB |
|---|---|---|
| 09:32 ET | 500 | 1.5 |
| 09:41 ET | 400 | 1.57 |
| 01:55 ET | 728 | 1.51 |
| 03:45 ET | 100 | 1.59 |
| 03:59 ET | 476 | 1.66 |
Apr 1, 2024
HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights, from 4:10PM ET on Monday Apr 01, 2024 by Dow Jones
4:10PM ET on Monday Apr 01, 2024 by Dow JonesPress Release: HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights, from 4:10PM ET on Monday Apr 01, 2024 by Dow Jones
4:10PM ET on Monday Apr 01, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
HCW Biologics Inc | 62.8M | -2.4x | --- |
Beyondspring Inc | 70.1M | -2.6x | --- |
MediciNova Inc | 68.7M | -8.0x | --- |
Rallybio Corp | 63.1M | -0.9x | --- |
RetinalGenix Technologies Inc | 62.2M | -29.1x | --- |
Lantern Pharma Inc | 62.0M | -3.9x | --- |
Company Information
HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions such as long-haul COVID-19. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth factor-β and stimulate immune cells, targeting senescent cells and the SASP factors they secrete. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, and others.
Contact Information
- Headquarters
- 2929 N Commerce Pkwy, Miramar, Fl 33025MIRAMAR, FL, United States 33025
- Phone
- 954-842-2024
- Fax
- 954-842-2037
Executives
- Independent Chairman of the Board
- Scott Garrett
- Chief Executive Officer, Founder, Director
- Hing Wong
- Chief Financial Officer
- Rebecca Byam
- Senior Vice President of Business Development
- Lee Flowers
- Chief Scientific Officer, Vice President of Clinical Operations
- Peter Rhode
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $62.8M |
|---|---|
Revenue (TTM) | $2.8M |
Shares Outstanding | 37.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.70 |
Book Value | $0.37 |
P/E Ratio | -2.4x |
Price/Sales (TTM) | 22.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -904.96% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
